carfenazine

CAS No. 2622-30-2

carfenazine( —— )

Catalog No. M28924 CAS No. 2622-30-2

carfenazine targets the Dopamine receptor and is used for schizophrenia research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 183 In Stock
10MG 275 In Stock
25MG 471 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    carfenazine
  • Note
    Research use only, not for human use.
  • Brief Description
    carfenazine targets the Dopamine receptor and is used for schizophrenia research.
  • Description
    carfenazine targets the Dopamine receptor and is used for schizophrenia research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    Calpain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2622-30-2
  • Formula Weight
    425.59
  • Molecular Formula
    C24H31N3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lon HK, et al. Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. Clin Pharmacol Drug Dev. 2019 Apr. 8(3):290.
molnova catalog
related products
  • JNJ-37822681

    JNJ-37822681 is a novel, highly selective dopamine D? receptor antagonist characterized by a rapid dissociation rate from the dopamine D? receptor.

  • Pridopidine

    Pridopidine (ACR16, FR-310826, ASP-2314, Huntexil) is a specific dopamine stabilizer without no partial agonism.

  • CCT241736

    CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3.